REFRESH
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension
- Stage
- klaar
- Medicine
- Firibastat
- Population
- Primaire preventie coronairlijden
- Phase
- III
- First Patient In
- 30 May 2022
- Last Patient In
- 28 October 2022
- Last Patient Last Visit
- 15 November 2022
Study Director
drs. H.G.R. Dorman
Cardioloog
Office Contact
